MCID: MYX001
MIFTS: 47

Myxopapillary Ependymoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myxopapillary Ependymoma

MalaCards integrated aliases for Myxopapillary Ependymoma:

Name: Myxopapillary Ependymoma 12 54 60 15 74
Ependymoma Myxopapillary 56

Characteristics:

Orphanet epidemiological data:

60
myxopapillary ependymoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adolescent,All ages,Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:5075
MeSH 45 D004806
NCIt 51 C3697
SNOMED-CT 69 1623000
ICD10 via Orphanet 35 D43.2
UMLS via Orphanet 75 C0205769
Orphanet 60 ORPHA251643
UMLS 74 C0205769

Summaries for Myxopapillary Ependymoma

NIH Rare Diseases : 54 Myxopapillary ependymoma (MEPN) is a slow-growing ependymoma (a type of glioma, which is a tumor that arises from the supportive tissue of the brain and spinal cord). They tend to occur in the lower part of the spinal column and are usually considered to be benign, low-grade or grade I tumors. The age of diagnosis ranges from 6 to 82 years. Symptoms of an ependymoma are related to the location and size of the tumor and may include nausea, vomiting, headache, pain, numbness, bowel or bladder symptoms, and various other signs and symptoms. The cause of ependymomas is unknown. They are known to recur locally (more commonly in individuals diagnosed in childhood). Treatment may vary depending on the location, grade, and whether the tumor has spread to the spine, but typically includes aggressive surgery. Management may also include chemotherapy and radiation therapy.

MalaCards based summary : Myxopapillary Ependymoma, also known as ependymoma myxopapillary, is related to ependymoma and secretory meningioma, and has symptoms including back pain An important gene associated with Myxopapillary Ependymoma is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Fentanyl and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and skin, and related phenotypes are ependymoma and abnormal conus terminalis morphology

Related Diseases for Myxopapillary Ependymoma

Diseases related to Myxopapillary Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Related Disease Score Top Affiliating Genes
1 ependymoma 31.3 GFAP MUC1 S100B VIM
2 secretory meningioma 30.5 MUC1 VIM
3 neurofibroma 30.4 MUC1 S100B
4 chordoma 29.9 GFAP MUC1 S100B VIM
5 chordoid meningioma 29.5 GFAP MUC1 S100B VIM
6 anaplastic ependymoma 29.5 GFAP MUC1 S100B VIM
7 benign ependymoma 11.9
8 siderosis 10.4
9 cutaneous leiomyosarcoma 10.3 GFAP MUC1
10 papillary ependymoma 10.3 GFAP S100B
11 lipomatosis, multiple 10.3
12 pilonidal sinus 10.3
13 meningioma, familial 10.3
14 pleomorphic lipoma 10.3
15 spinal meningioma 10.3
16 cauda equina syndrome 10.3
17 tethered cord syndrome 10.3
18 superficial siderosis 10.3
19 gemistocytic astrocytoma 10.3 GFAP S100B
20 localized hypertrophic neuropathy 10.2 MUC1 S100B
21 sclerosing perineurioma 10.2 MUC1 S100B
22 dysembryoplastic neuroepithelial tumor 10.2 GFAP S100B
23 reticular perineurioma 10.2 MUC1 S100B
24 non-functioning pituitary adenoma 10.2 MUC1 S100B
25 functioning pituitary adenoma 10.2 MUC1 S100B
26 pineocytoma 10.2 GFAP S100B
27 epithelioid malignant peripheral nerve sheath tumor 10.2 MUC1 S100B
28 aggressive digital papillary adenocarcinoma 10.2 MUC1 S100B
29 spiradenoma 10.2 MUC1 S100B
30 spinal cancer 10.2 GFAP HOXB13
31 subependymal giant cell astrocytoma 10.2 GFAP S100B
32 traumatic brain injury 10.2 GFAP S100B
33 brain injury 10.2 GFAP S100B
34 meningeal melanocytoma 10.2 MUC1 S100B
35 lung combined type small cell carcinoma 10.2 GFAP NCAM1
36 intraneural perineurioma 10.2 MUC1 S100B
37 neuroma 10.2 GFAP S100B
38 ovarian serous cystadenofibroma 10.2 MUC1 NCAM1
39 cystadenofibroma 10.1 MUC1 NCAM1
40 transitional meningioma 10.1 MUC1 NCAM1
41 ganglioglioma 10.1 GFAP S100B
42 subependymoma 10.1 GFAP NCAM1
43 pseudomyxoma peritonei 10.1 CA2 MUC1
44 epidermoid cysts 10.1
45 renal cell carcinoma, nonpapillary 10.1
46 down syndrome 10.1
47 chondrosarcoma 10.1
48 temporal lobe epilepsy 10.1
49 paraganglioma 10.1
50 colorectal adenocarcinoma 10.1

Graphical network of the top 20 diseases related to Myxopapillary Ependymoma:



Diseases related to Myxopapillary Ependymoma

Symptoms & Phenotypes for Myxopapillary Ependymoma

Human phenotypes related to Myxopapillary Ependymoma:

60 33 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ependymoma 60 33 obligate (100%) Obligate (100%) HP:0002888
2 abnormal conus terminalis morphology 60 33 hallmark (90%) Very frequent (99-80%) HP:0031938
3 vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002013
4 headache 60 33 frequent (33%) Frequent (79-30%) HP:0002315
5 unsteady gait 60 33 frequent (33%) Frequent (79-30%) HP:0002317
6 abnormal large intestine physiology 60 33 frequent (33%) Frequent (79-30%) HP:0012700
7 neck pain 60 33 frequent (33%) Frequent (79-30%) HP:0030833
8 autonomic bladder dysfunction 60 33 frequent (33%) Frequent (79-30%) HP:0005341
9 neoplasm of the skin 60 33 occasional (7.5%) Occasional (29-5%) HP:0008069
10 abnormal sacrum morphology 60 33 occasional (7.5%) Occasional (29-5%) HP:0005107
11 abnormality of the auditory canal 60 33 very rare (1%) Very rare (<4-1%) HP:0000372
12 neoplasm of the central nervous system 60 Frequent (79-30%)

UMLS symptoms related to Myxopapillary Ependymoma:


back pain

GenomeRNAi Phenotypes related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 8.8 MUC1 NCAM1 VIM

Drugs & Therapeutics for Myxopapillary Ependymoma

Drugs for Myxopapillary Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
3
Dopamine Approved Phase 3,Early Phase 1 62-31-7, 51-61-6 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Narcotics Phase 3
7 Adjuvants, Anesthesia Phase 3
8 Analgesics Phase 3
9 Anesthetics, Intravenous Phase 3
10 Liver Extracts Phase 3,Phase 2,Phase 1
11 Anesthetics, General Phase 3
12 Anesthetics Phase 3
13 Analgesics, Opioid Phase 3
14 Central Nervous System Depressants Phase 3
15 Peripheral Nervous System Agents Phase 3
16 Cola Phase 3,Phase 1
17 Cholinesterase Inhibitors Phase 3,Phase 2
18 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1
19 Nootropic Agents Phase 3,Phase 2
20 Cholinergic Agents Phase 3,Phase 2
21 Central Nervous System Stimulants Phase 3,Phase 2
22 Dopamine Agents Phase 3,Early Phase 1
23 Dexmethylphenidate Hydrochloride Phase 3
24 Dopamine Uptake Inhibitors Phase 3
25 Neurotransmitter Uptake Inhibitors Phase 3
26
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
27
Etoposide Approved Phase 2 33419-42-0 36462
28
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
29
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
30
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
31
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
32
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
33
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
34
leucovorin Approved Phase 2 58-05-9 143 6006
35
Sodium Citrate Approved, Investigational Phase 2 68-04-2
36
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
37
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
38
Tamoxifen Approved Phase 2 10540-29-1 2733526
39
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2 7553-56-2 807
40
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
41
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
42
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
43
Promethazine Approved, Investigational Phase 2 60-87-7 4927
44
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
45
Acetaminophen Approved Phase 2 103-90-2 1983
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
48
Doxil Approved June 1999 Phase 2 31703
49 Antineoplastic Agents, Alkylating Phase 2,Phase 1
50 Alkylating Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
5 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
6 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
7 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
8 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
9 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
10 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
11 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
12 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
13 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
14 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
15 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
16 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
17 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
18 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
19 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
20 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
21 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
22 Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma Completed NCT00401024 Phase 1 imatinib mesylate
23 Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas Completed NCT00002753 Phase 1
24 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
25 Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor Completed NCT00069940 Phase 1
26 Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
27 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
28 CC-5013 in Treating Patients With Recurrent Glioma Completed NCT00036894 Phase 1 lenalidomide
29 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
30 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel
31 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
32 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
33 Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Terminated NCT00003567 Phase 1 O6-benzylguanine;carmustine;temozolomide
34 Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma Completed NCT00005082 Not Applicable
35 Study of Blood and Cheek Cell Samples From Patients With Glioma Completed NCT01009307
36 Study of Tissue Samples From Patients With Glioma or Other Brain Tumors Completed NCT00967200
37 Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors Completed NCT00499798
38 Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders Completed NCT00255671
39 Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma Active, not recruiting NCT01165632 Early Phase 1 fluorine F 18 fluorodopa
40 Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma Terminated NCT00430079 Not Applicable etanidazole
41 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable
42 Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors Withdrawn NCT00005790 Not Applicable

Search NIH Clinical Center for Myxopapillary Ependymoma

Genetic Tests for Myxopapillary Ependymoma

Anatomical Context for Myxopapillary Ependymoma

MalaCards organs/tissues related to Myxopapillary Ependymoma:

42
Brain, Spinal Cord, Skin, Temporal Lobe, Bone, Kidney, Pituitary

Publications for Myxopapillary Ependymoma

Articles related to Myxopapillary Ependymoma:

(show top 50) (show all 186)
# Title Authors Year
1
Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature. ( 30321682 )
2019
2
Myxopapillary Ependymoma. ( 30844350 )
2019
3
Resection of Myxopapillary Ependymoma of the Filum Terminale: 2-Dimensional Operative Video. ( 31073602 )
2019
4
Myxopapillary ependymoma with anaplastic features: A case report with review of the literature. ( 30294495 )
2018
5
Isolated myxopapillary ependymoma of the fourth ventricle: case report and review of literature. ( 30317890 )
2018
6
An Extremely Rare Case of Back and Hip Pain due to the Metastasis of Late Recurrent Myxopapillary Ependymoma to the Inguinal Lymph Node. ( 29166763 )
2018
7
Metastases of spinal myxopapillary ependymoma: unique characteristics and clinical management. ( 29219779 )
2018
8
Myxopapillary Ependymoma of Lumbar Soft Tissue: A Case Report With Gene Expression Evaluation. ( 29254456 )
2018
9
Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. ( 29270703 )
2018
10
Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. ( 29380114 )
2018
11
Teaching Case 2-2018: Sclerosing myxopapillary ependymoma mimicking whorling-sclerosing meningioma. ( 29436365 )
2018
12
Anaplastic myxopapillary ependymoma in an infant: Case report and literature review. ( 28580214 )
2017
13
Spinal myxopapillary ependymoma presenting with low back pain and subarachnoid hemorrhage. ( 28737370 )
2017
14
Occipital Intraparenchymal Myxopapillary Ependymoma: Case Report and Literature Review. ( 29114296 )
2017
15
Primary Seeding of Myxopapillary Ependymoma: Different Disease in Adult Population? Case Report and Review of Literature. ( 28040529 )
2017
16
Spinal myxopapillary ependymoma with interval drop metastasis presenting as cauda equina syndrome: case report and review of literature. ( 27757435 )
2016
17
Synchronous Sacrococcygeal Myxopapillary Ependymoma and Chordoma. ( 26464159 )
2016
18
An unusual cause of low back pain in a young adult: myxopapillary ependymoma of the filum terminale. ( 26657487 )
2016
19
Intradural extramedullary non-myxopapillary ependymoma with a lumbar nerve root involvement in a Japanese man. ( 26852964 )
2016
20
Surgical treatment for posttraumatic hemorrhage inside a filum terminale myxopapillary ependymoma: a case report and literature review. ( 27015688 )
2016
21
Lumbar corpectomy for correction of degenerative scoliosis from osteoradionecrosis reveals a delayed complication of lumbar myxopapillary ependymoma. ( 27056674 )
2016
22
Spinal myxopapillary ependymoma in an adult male presenting with recurrent acute low back pain: a case report. ( 27092234 )
2016
23
Concomitant Double Tumors of Myxopapillary Ependymoma Presented at Cauda Equina-Filum Terminale in Adult Patient. ( 27123029 )
2016
24
Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. ( 27306443 )
2016
25
Uterine Cervix Metastasis of Myxopapillary Ependymoma Originated from the Spinal Cord. ( 27403397 )
2016
26
Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. ( 27423644 )
2016
27
Primary multifocal myxopapillary ependymoma of the filum terminale. ( 26154385 )
2016
28
Unspecific clinical manifestation of cauda equina myxopapillary ependymoma. ( 26396623 )
2015
29
Outcome predictors in the management of spinal myxopapillary ependymoma: an integrative survival analysis. ( 25108296 )
2015
30
A rare case of extramedullary myxopapillary ependymoma. ( 25280929 )
2015
31
Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. ( 25301811 )
2015
32
Myxopapillary ependymoma: Lesser known cytomorphologic features. ( 25948946 )
2015
33
Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. ( 26235025 )
2015
34
Disseminated adult spinal extramedullary myxopapillary ependymoma. ( 26253989 )
2015
35
Disseminated spinal myxopapillary ependymoma in an adult at initial presentation: a case report and review of the literature. ( 24460084 )
2014
36
Lumbar spine neuroarthropathy (Charcot joint) caused by a myxopapillary ependymoma. ( 24477624 )
2014
37
Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. ( 24818785 )
2014
38
Spinal drop metastasis in myxopapillary ependymoma: a case report and a review of treatment options. ( 25002955 )
2014
39
Myxopapillary ependymoma in children: a study of 11 cases and a comparison with the adult experience. ( 25066546 )
2014
40
Pediatric myxopapillary ependymoma treated with subtotal resection and radiation therapy: a case report and review of the literature. ( 25082377 )
2014
41
Myxopapillary ependymoma of filum terminale. ( 25181852 )
2014
42
Spontaneous rupture and hemorrhage of myxopapillary ependymoma of the filum terminale: a case report and literature review. ( 25264068 )
2014
43
Myxopapillary ependymoma masquerading as subcutaneous sacrococcygeal non-healing ulcer: case report. ( 25266190 )
2014
44
Myxopapillary ependymoma of the cauda equina in a 5-year-old boy. ( 25558331 )
2014
45
Myxopapillary ependymoma of the conus medullaris presenting with intratumoral hemorrhage during weight lifting in a teenager. ( 23821248 )
2014
46
The nature of double concomitant myxopapillary ependymoma: report of a case. ( 23904042 )
2014
47
Cytopathologic characteristics and differential diagnostic considerations of osteolytic myxopapillary ependymoma. ( 23913845 )
2014
48
Primary cerebral myxopapillary ependymoma presenting with intratumoral hemorrhage. ( 24229008 )
2014
49
Clinicopathological features of myxopapillary ependymoma. ( 24332590 )
2014
50
Concomitant intramedullary pilocytic astrocytoma and conus medullaris myxopapillary ependymoma: a case report. ( 21688235 )
2013

Variations for Myxopapillary Ependymoma

Expression for Myxopapillary Ependymoma

Search GEO for disease gene expression data for Myxopapillary Ependymoma.

Pathways for Myxopapillary Ependymoma

Pathways related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 CA2 GFAP NCAM1 S100B
2 10.82 GFAP NCAM1 S100B VIM
3 10.75 MUC1 NCAM1

GO Terms for Myxopapillary Ependymoma

Biological processes related to Myxopapillary Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to wounding GO:0009611 9.43 GFAP HOXB13
2 negative regulation of neuron projection development GO:0010977 9.4 GFAP VIM
3 long-term synaptic potentiation GO:0060291 9.37 GFAP S100B
4 morphogenesis of an epithelium GO:0002009 9.32 CA2 HOXB13
5 intermediate filament organization GO:0045109 9.26 GFAP VIM
6 astrocyte development GO:0014002 9.16 GFAP VIM
7 Bergmann glial cell differentiation GO:0060020 8.96 GFAP VIM
8 intermediate filament-based process GO:0045103 8.62 GFAP VIM

Sources for Myxopapillary Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....